“Bone metastasis in Solid Tumor Market 2034”
The Bone metastasis in Solid Tumor market growth is driven by factors like increase in the prevalence of Bone metastasis in Solid Tumor, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Bone metastasis in Solid Tumor market report also offers comprehensive insights into the Bone metastasis in Solid Tumor market size, share, Bone metastasis in Solid Tumor epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bone metastasis in Solid Tumor market size growth forward.
Some of the key highlights from the Bone metastasis in Solid Tumor Market Insights Report:
-
Several key pharmaceutical companies, including Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others, are developing novel products to improve the Bone metastasis in Solid Tumor treatment outlook.
-
In December 2024, Halozyme Therapeutics revealed that the FDA approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) from Bristol Myers Squibb. This co-formulation, utilizing Halozyme’s ENHANZE® technology, marks the first subcutaneous PD-1 inhibitor approved for several adult solid tumor indications, both as a standalone treatment and in combination therapies.
-
Bone metastasis in solid tumors occurs when cancer cells detach from a primary tumor, spread through the bloodstream or lymphatic system, and form secondary tumors in the bones. This condition is more common than primary bone cancers, particularly in adults, and is frequently linked with serious complications. Bone metastasis is the third most common site of metastasis after the lungs and liver, affecting approximately 70% of patients with breast and prostate cancer—the two most prevalent cancers globally. Other cancers, such as kidney, lung, thyroid, bladder, and ovarian, also commonly spread to bones.
-
Pain is the most prevalent and significant symptom of bone metastasis, but it can also lead to fractures, hypercalcemia, and spinal cord or nerve compression. Bone metastasis disrupts normal bone remodeling, which is regulated by osteoclasts and osteoblasts. Based on its impact on bone remodeling, bone metastasis is classified into osteolytic, osteoblastic, or mixed types.
-
To assess bone turnover and hypercalcemia, blood tests such as CBC, serum calcium, alkaline phosphatase, and vitamin D levels are performed. Imaging tests like bone scans, PET scans, CT scans, MRIs, and X-rays, as well as biopsies, are essential for diagnosing bone metastasis.
-
In 2023, the United States had the highest number of bone metastasis cases among the 7MM, with breast cancer accounting for about 41% of these cases. Among the EU4 and the UK, males had a higher incidence of bone metastasis in solid tumors. The most common medications for managing bone issues in these patients include bisphosphonates (pamidronate, zoledronic acid) and denosumab.
-
The United States dominated the market for bone metastasis in solid tumors in 2023, holding nearly 70% of the market share compared to EU4, the UK, and Japan. Among the EU4 and UK, Germany had the largest market share, while Spain had the smallest.
-
A few drugs are currently in the clinical development phase for treating bone metastasis from solid tumors like prostate, breast, lung cancers, osteosarcoma, and Ewing’s sarcoma. Cabozantinib, an emerging therapy, shows promise in improving survival for patients with bone metastasis, enhancing both survival and quality of life. Other therapies are also under investigation by companies such as Actuate Therapeutics and QSAM Therapeutics.
-
Despite advancements in treatment, further understanding of the mechanisms behind bone metastasis across various cancers is needed. Clinical challenges such as improving prediction, early diagnosis, and treatment through biomarkers and therapeutic targets remain. Larger, long-term studies are necessary to confirm the efficacy of current treatments.
-
As per DelveInsight analysis, the Bone metastasis in Solid Tumor market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Bone metastasis in Solid Tumor Market Landscape
Bone metastasis in Solid Tumor Overview
Bone metastasis in Solid Tumor (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.
Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett’s esophagus, and esophageal adenocarcinoma if not treated.
Do you know the treatment paradigms for different countries? Download our Bone metastasis in Solid Tumor Market Sample Report
Bone metastasis in Solid Tumor Epidemiology Insights
-
In 2023, the Bone Metastasis in Solid Tumors market size was approximately USD 1,700 million, and it is projected to grow throughout the study period (2020–2034) across the 7MM.
Bone metastasis in Solid Tumor Epidemiology Segmentation
DelveInsight’s Bone metastasis in Solid Tumor market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Bone metastasis in Solid Tumor historical patient pools and forecasted Bone metastasis in Solid Tumor patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bone metastasis in Solid Tumor Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Bone metastasis in Solid Tumor Prevalence
-
Age-Specific Bone metastasis in Solid Tumor Prevalence
-
Gender-Specific Bone metastasis in Solid Tumor Prevalence
-
Diagnosed and Treatable Cases of Bone metastasis in Solid Tumor
Visit for more @ Bone metastasis in Solid Tumor Epidemiological Insights
Bone metastasis in Solid Tumor Market Outlook
Bone is a common site for metastasis in patients with advanced cancer. While bone metastases can occur with any solid tumor, they are most frequently seen in patients with breast, prostate, lung cancer, and renal cell carcinoma. The clinical management of bone metastasis primarily focuses on alleviating pain, preventing bone complications, and maintaining quality of life. Bone-targeting agents (BTA), such as XGEVA (denosumab) and bisphosphonates like zoledronic acid, pamidronate, ibandronate, clodronate, and alendronate, are commonly used treatments to prevent skeletal-related events (SREs) in patients with bone metastasis.
In addition to these treatments, Bayer’s XOFIGO was approved by the US FDA in May 2013 for castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. While XOFIGO has shown significant efficacy in treating prostate cancer with bone metastases, it is typically introduced after the disease has become symptomatic, limiting its use due to its specific indication and lower real-world treatment preference.
Studies have shown that patient adherence to bone-targeted therapy has been suboptimal, with high rates of treatment discontinuation and switching. These factors have been taken into account when estimating the market size for bone metastasis in solid tumors.
Bone metastasis in Solid Tumor Marketed Drugs
Bone metastasis in Solid Tumor Emerging Drugs
Bone metastasis in Solid Tumor Key Companies
-
Mabwell (Shanghai) Bioscience Co., Ltd., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche, and others
For more information, visit Bone metastasis in Solid Tumor Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Bone metastasis in Solid Tumor Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Bone metastasis in Solid Tumor, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Bone metastasis in Solid Tumor epidemiology in the 7MM
-
Bone metastasis in Solid Tumor marketed and emerging therapies
-
Bone metastasis in Solid Tumor companies
-
Bone metastasis in Solid Tumor market drivers and barriers
Table of Contents:
1 Bone metastasis in Solid Tumor Market Key Comprehensive Insights
2 Bone metastasis in Solid Tumor Market Report Introduction
3 Competitive Intelligence Analysis for Bone metastasis in Solid Tumor
4 Bone metastasis in Solid Tumor Market Analysis Overview at a Glance
5 Executive Summary of Bone metastasis in Solid Tumor
6 Bone metastasis in Solid Tumor Epidemiology and Market Methodology
7 Bone metastasis in Solid Tumor Epidemiology and Patient Population
8 Bone metastasis in Solid Tumor Patient Journey
9 Bone metastasis in Solid Tumor Treatment Algorithm, Bone metastasis in Solid Tumor Current Treatment, and Medical Practices
10 Key Endpoints in Bone metastasis in Solid Tumor Clinical Trials
11 Bone metastasis in Solid Tumor Marketed Therapies
12 Bone metastasis in Solid Tumor Emerging Therapies
13 Bone metastasis in Solid Tumor: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Bone metastasis in Solid Tumor
16 Bone metastasis in Solid Tumor Market Key Opinion Leaders Reviews
18 Bone metastasis in Solid Tumor Market Drivers
19 Bone metastasis in Solid Tumor Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Bone metastasis in Solid Tumor Epidemiology 2034
DelveInsight’s “Bone metastasis in Solid Tumor – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Bone metastasis in Solid Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Bone metastasis in Solid Tumor Pipeline 2024
“Bone metastasis in Solid Tumor Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bone metastasis in Solid Tumor market. A detailed picture of the Bone metastasis in Solid Tumor pipeline landscape is provided, which includes the disease overview and Bone metastasis in Solid Tumor treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics
